Systemic toxicological safety of oral 5-deazaflavin TND1128 used in anti-aging practice: a secondary assessment of publicly disclosed hepatic signals

The human body is a complex machine where a treatment intended for one part can sometimes ripple out to affect another. This is a fundamental truth in medicine: a pill taken to smooth skin or slow the visible signs of aging travels through the bloodstream, reaching the liver, the heart, and the brain. While the goal might be to look younger, the risk is that the very substance meant to help could inadvertently harm an internal organ. This is particularly relevant for new compounds that are marketed for aesthetic purposes but have not yet been thoroughly tested in large groups of people. Scientists call this the difference between a local effect, which stays where it is applied, and a systemic effect, which spreads throughout the entire body. When a new substance is introduced for human use, the most critical question is not just whether it works, but whether it is safe for the organs that process it, especially the liver, which acts as the body's primary filter.

In the world of anti-aging research, a synthetic compound known as TND1128 has gained attention. It is a man-made version of a chemical family called 5-deazaflavins, which are studied for their ability to influence how cells produce energy. In laboratory settings using mouse cells, researchers have observed that this substance can change how neurons behave and how mitochondria, the tiny power plants inside cells, function. These early studies suggested the compound might have biological activity worth exploring. However, a gap has emerged between these laboratory findings and real-world human use. While the science in a petri dish is one thing, taking a substance orally as a daily supplement is another matter entirely. The safety of a drug is not proven just because it works in a mouse brain slice; it must be proven in people, with careful tracking of what happens to their internal organs over time.

A recent analysis by an independent researcher set out to examine the safety record of TND1128 as it is currently being used in Japan. The goal was not to determine if the drug cures aging, but to see if there were any warning signs of harm, specifically to the liver. The researcher gathered every piece of publicly available information up to late September 2026. This included peer-reviewed scientific papers, official government trial registries, and reports from medical conferences. The search was meticulous, looking for any mention of the compound's use in humans and any reports of side effects. The investigation focused on whether the available data was strong enough to confirm a danger or if it was simply a signal that required more careful watching.

The search revealed a stark contrast between the scientific literature and the clinical reality. There are three published scientific papers about TND1128, but all of them are preclinical studies conducted on mice or in test tubes. None of these papers reported on the safety of the drug in human beings. They described how the compound affected calcium levels in brain tissue or how it changed the energy potential of cells, but they did not test it on people. Despite this lack of formal human safety data, the compound is being used in practice. A report from a 2024 medical conference in Japan stated that the drug had been prescribed over one thousand times to patients taking 100 milligrams once a day. This indicates that the substance is already circulating in the human population, even though no formal, peer-reviewed study has yet confirmed its safety profile.

The most significant finding of this analysis is the presence of a safety signal regarding liver health. In the 2024 conference report, the treating physicians noted two cases where patients experienced liver dysfunction, marked by elevated levels of enzymes called AST and ALT. These enzymes are released into the blood when liver cells are damaged. A later disclosure from the same medical institution confirmed that these two cases were not isolated; additional cases of liver issues were observed. Crucially, the doctors reported that in all the cases they disclosed, the liver function improved after the patients stopped taking the supplement. This pattern, where a problem appears during use and resolves when the substance is removed, is a classic sign that the substance might be the cause. However, the researchers emphasized that this is a signal, not a final verdict.

The analysis carefully explained why this signal cannot yet be turned into a confirmed diagnosis of drug-induced liver injury. To make such a diagnosis, doctors need specific details that are currently missing from the public record. They need to know the exact numbers of the enzyme levels, how high they went compared to normal limits, and whether other liver markers like bilirubin were affected. They also need to know how long it took for the damage to appear after the patient started the drug, and whether the patients were taking other medications, drinking alcohol, or had other health conditions that could have caused the liver trouble. Without these details, it is impossible to rule out other causes or to calculate how common the problem is. The report noted that the number "one thousand" referred to the total number of prescriptions written, not the number of unique people, so it is impossible to say what percentage of users were affected.

The researcher also looked for any ongoing studies that might provide better answers. A clinical trial was registered in Japan in 2026 to study the safety and effectiveness of TND1128 in adults. The study aimed to enroll ten participants and was still recruiting at the time of the analysis. No results from this study had been published yet. This means that the current understanding of the drug's safety relies entirely on the initial reports from the treating doctors and the absence of any formal human safety data in scientific journals. The lack of a dedicated safety study is a significant gap, especially since the drug is being used orally by people who are not part of a controlled research environment.

The conclusion of the paper is a call for caution and better data. The evidence suggests that TND1128 poses a potential risk to the liver, but the current information is too incomplete to say exactly how big that risk is or how severe it can be. The researchers argue that anyone continuing to use this substance should be monitored closely. This means checking liver function tests regularly and keeping a detailed record of when the drug is started and stopped, what other substances are being taken, and exactly how the liver markers change over time. The report also suggests that if patients show signs of pancreatic trouble, such as abdominal pain, doctors should check enzymes related to the pancreas as well, though there is no current evidence that the drug harms the pancreas.

Ultimately, this analysis serves as a reminder that the path from a promising laboratory discovery to a safe, everyday supplement is long and requires rigorous testing. The fact that a substance shows interesting effects in a mouse brain does not guarantee it is safe for a human liver. The presence of a safety signal means that the story is not over; it means that more information is needed before the full picture can be understood. Until more structured data is available, the use of TND1128 remains an experiment in progress, one where the safety of the users depends on careful observation and transparent reporting of any changes in their health. The researchers did not declare the drug unsafe, but they made it clear that the current evidence is insufficient to declare it safe either, leaving the responsibility on the medical community to gather the missing pieces of the puzzle.